Published in Drug Week, July 22nd, 2005
Gordon McCauley, president and CEO of Allon, said that subject to FDA approval, the company will commence a phase I clinical trial during Q3 2005 evaluating the safety, tolerability, and pharmacokinetics of AL-208 in healthy adults. The company expects the phase I trials to be complete in Q4 2005...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.